Scientists from The Feinstein Institutes for Medical Research have announced the publication of results from a phase 3 clinical trial looking at the safety and efficacy of the oral neuroactive steroid zuranolone (30mg) in the treatment of patients with postpartum depression (PPD). The findings published in the Journal of the American Medical Association (JAMA) Psychiatry showed that after two weeks of daily treatment, women treated…
